Skip to search formSkip to main contentSkip to account menu

Eudragit RL

Known as: Eudragit retard L 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Polymers

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Evaluation of polymer carriers with regard to the bioavailability enhancement of bifendate solid dispersions prepared by hot-melt extrusion
Objective: The aim of this study was to evaluate several polymer carriers with regard to the bioavailability enhancement of… 
2011
2011
Drug release mechanisms from Kollicoat SR:Eudragit NE coated pellets.
Highly Cited
2010
Highly Cited
2010
Properties of melt extruded enteric matrix pellets.
2008
2008
Formulation and evaluation of intragastric floating drug delivery system of diltiazem hydrochloride
The present study is aimed towards formulation and evaluation of floating multiparticulate oral drug delivery system of diltiazem… 
Highly Cited
2004
Highly Cited
2004
Identification of Phase Separation in Solid Dispersions of Itraconazole and Eudragit® E100 Using Microthermal Analysis
AbstractPurpose. To evaluate the phase separation in itraconazole/Eudragit® E100 solid dispersions prepared by hot-stage… 
Highly Cited
2003
Highly Cited
2003
Influence of Eudragit® NE 30 D Blended with Eudragit® L 30 D-55 on the Release of Phenylpropanolamine Hydrochloride from Coated Pellets
Abstract The objective of this study was to investigate the influence of Eudragit® NE 30 D blended with Eudragit® L 30 D-55 on… 
2000
2000
Reversibly soluble biocatalyst: optimization of trypsin coupling to Eudragit S-100 and biocatalyst activity in soluble and precipitated forms.
1999
1999
Studies on controlled release dimenhydrinate from matrix tablet formulations.
Highly Cited
1996
Highly Cited
1996
Influence of plasticizer concentration and storage conditions on the drug release rate from Eudragit® RS30D film-coated sustained-release theophylline pellets
The influence of triethylcitrate (TEC) concentration and storage conditions (temperature and relative humidity) on the release of… 
Review
1989
Review
1989
Mesalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in chronic inflammatory bowel disease.
Mesalazine (5-aminosalicylic acid; mesalamine), the active moiety of sulphasalazine (salazosulfapyridine), is available in… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)